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Abstract. Cachexia is a common systemic manifestation. 
Additionally, myostatin is known to be a negative regulator 
of skeletal muscle development. The present study aimed to 
investigate whether formoterol down-regulates the myostatin 
system in skeletal muscle of tumour-bearing rats. Real-time 
PCR and Western blotting were used for the analysis. Results 
showed that rats bearing the Yoshida AH-130 ascites hepa-
toma, a cachexia-inducing tumour, exhibited marked muscle 
wasting that affected the mass of the muscles studied. The 
cachectic animals exhibited a significant increase in the 
mRNA levels of the myostatin receptor (ActIIB) in gastroc-
nemius muscles. Notably, the expression of the various forms 
of follistatin, a protein with the opposite effects to those 
of myostatin, was significantly reduced as a result of the 
implantation of the tumour. When the animals were treated 
with formoterol, a β-agonist with anti-cachectic potential, 
increases in skeletal muscle weights were observed. The 
β-agonist significantly increased levels of various follistatin 
isoforms and significantly decreased the expression levels 
of the myostatin receptor. In addition, formoterol treatment 
resulted in a significant decrease of the myostatin protein 
content of the gastrocnemius muscle. In conclusion, the results 
presented indicate that certain anabolic actions of formoterol 
on the skeletal muscle of cachectic animals may be mediated 
via the myostatin system.
Introduction
In advanced malignant diseases, cachexia appears to be one 
of the most common systemic manifestations. The presence 
of cachexia always indicates a poor prognosis, having a 
marked impact on the patients' quality of life and survival (1). 
Several important molecular mechanisms have been shown 
to be involved in the increased muscle catabolism observed 
in cancer-induced cachexia, such as greater ubiquitin-
proteasome-dependent proteolysis, apoptosis, and activation 
of uncoupling proteins (2-5). Interaction of these mechanisms 
leads to muscle-mass loss by promoting protein and DNA 
breakdown and energy inefficiency.
Myostatin, also known as growth and differentiation 
factor-8 (GDF factor-8), which was cloned in 1997, is a 
member of the transforming growth factor-β (TGF-β) super-
family of secreted growth factors. It is a negative regulator of 
skeletal muscle development (6-8). During the embryogenetic 
process, myostatin expression is only observed in developing 
skeletal muscles, but the protein continues to be expressed and 
secreted by skeletal muscles during adult life (9,10). Mice and 
cattle with genetic deficiencies in myostatin exhibit marked 
increases in skeletal muscle mass, thus supporting the role of 
myostatin in supressing muscle growth (11). Myostatin acts 
systemically (it is produced in muscle and adipose tissue and 
released in the circulation) and binds to cell-surface receptors, 
causing muscle loss. The myostatin protein can be detected 
in the circulation as a full-length precursor that is cleaved 
into an amino-terminal pro-peptide and a carboxy-terminal 
mature region, which is the active form of the peptide. In 
skeletal muscle and circulation, myostatin is detected in inac-
tive complexes of differing composition with other proteins, 
including its own pro-peptide, follistatin-like 3 (Fstl3, also 
known as follistatin-related gene), and latent TGFβ binding 
protein (12-15). The mechanism of activation of these inac-
tive complexes (or whether they can be activated at all) is 
unknown. For complexes containing the pro-peptide, activa-
tion likely requires proteolysis of the pro-peptide, possibly by 
specific target cells (16,17). Once activated, myostatin has a 
high affinity for the activin IIB receptor (Acvr2b, also known 
as ActRIIB) and a weak affinity for Acvr2a (also known as 
ActRII and ActRIIA), both of which, as with other receptors 
for TGF-β family members, bind multiple ligands (18).
Skeletal muscle possesses the ability to respond and adapt 
to changing environmental stimuli, leading to a set of meta-
bolic and morphological adaptations, which allow it to better 
meet the energy demands of sustained physical activity. Active 
myostatin binds to its receptor ActRIIB with high affinity 
and regulates the expression of target genes through a TGF-β 
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signaling pathway (10). Myostatin signaling acts through 
this receptor on skeletal muscle by activating an intracel-
lular cascade of events. First, there is presumed recruitment 
of a type I co-receptor. Thus, activin receptor-like kinases 4 
and/or 5 (ALK-4, ALK-5) are candidate coreceptors that are 
phosphorylated by ActRIIB. This activates phosphorylation of 
TGF-α-specific Smads 2 and 3, which form a complex with 
Smad 4. The Smad 2/3/4 complex is translocated to the nucleus 
to regulate the expression of targeted genes such as MyoD 
and other myogenic regulatory factors (19). Myostatin also 
activates the p38 MAPK, Erk1/2 and Wnt pathways (10,19-22). 
Inhibition of myostatin by injection of neutralizing antibodies 
or antagonists causes an increase in skeletal muscle mass, 
thus myostatin inhibitors exhibit great potential as candidates 
for treatment of muscle-wasting diseases (15,23). Conversely, 
the ectopic expression of myostatin induces atrophy in adult 
skeletal muscle by decreasing muscle structural genes such 
as those of myofibrillar proteins (myosin heavy-chain IIb, 
troponin I and desmin) and myogenic transcription factors 
(MyoD and myogenin) (24). Myostatin induces muscle 
wasting by activating the ubiquitin proteolytic system. The 
ubiquitin-associated genes atrogin-1, MuRF-1 and E214k 
are upregulated following myostatin treatment (25). Of note, 
myostatin signaling is able to inhibit Akt phosphorylation, thus 
downregulating the IGF-1/PI3K/AKT hypertrophy pathway. 
In addition, myostatin increases the levels of the active form 
of the transcription factor FoxO1, allowing for increased 
expression of atrophy-related genes (atrogenes). Notably, myo-
statin does not exert its action through NF-κB (25).
β2-adrenergic agonists are potent muscle growth 
promoters in many animal species (26,27), resulting in skel-
etal muscle hypertrophy (28-31). Formoterol is one of these 
compounds with important anti-cachectic effects in animal 
models. The model of action of this drug is based on its ability 
to prevent muscle-wasting by inhibiting proteolysis in skeletal 
muscle. Thus, this β2-agonist decreases the activation of the 
ubiquitin-dependent proteolytic system, the main mechanism 
activated in muscle-wasting conditions (32). In addition to its 
anti-proteolytic effects, formoterol decreases muscle apop-
tosis in muscle-wasting animals (32).
Bearing the above in mind, the aim of the present study 
was, in addition to observing the myostatin gene expression 
in a catabolic condition characterised by profound muscle-
wasting implantation of the Yoshida AH-130 ascites hepatoma, 
to test the hypothesis that certain anabolic actions of formoterol 
on skeletal muscle (32) involve the myostatin system.
Materials and methods
Animals. Male Wistar rats (Interfauna, Barcelona, Spain) of 
5 weeks of age were used in the experiments. The animals 
were maintained at 22±2˚C with a regular light-dark cycle 
(light on from 08:00 a.m. to 08:00 p.m.) and had free access 
to food and water. The food intake was measured daily. All 
animal manipulations were performed in accordance with 
the European Community guidelines for the use of labora-
tory animals.
Tumour inoculation and formoterol treatment. Rats were 
divided into control and tumour host groups. The latter 
group received an intraperitoneal inoculum of 108 AH-130 
Yoshida ascites hepatoma cells obtained from exponential 
tumours (33). The two groups were further divided into 
treated and untreated sub-groups, the former being admin-
istered a daily subcutaneous dose of formoterol [0.3 mg/kg 
body weight (bw), dissolved in physiological solution], and 
the latter the corresponding volume of solvent. On day 7 
after tumour transplantation, the animals were weighed and 
anaesthetised with an intra-peritoneal injection of ketamine/
xylazine mixture (3:1) (Imalgene® and Rompun®, respec-
tively). The tumour was harvested from the peritoneal cavity 
and its volume and cellularity were evaluated. Tissues were 
rapidly excised, weighed, and frozen in liquid nitrogen.
Real-time PCR. Total RNA from the gastrocnemius muscle 
was extracted by TriPure™ kit (Roche, Barcelona, Spain), a 
commercial modification of the acid guanidinium isothiocya-
nate/phenol/chloroform method (34).
First-strand cDNA was synthesised from total RNA with 
oligo dT15 primers and random primers pdN6 using a cDNA 
synthesis kit (Transcriptor Reverse Transcriptase, Roche, 
Barcelona, Spain). Analysis of mRNA levels for myostatin, 
ActIIB, FLST288, FLST315, FLST-L3 and Ub was performed 
with primers designed to detect these products: myostatin 
(Forward, 5' CTA CCA CGG AAA CAA TCA TTA CCA 3'; 
Reverse, 5' AGC AAC ATT TGG GCT TTC CAT 3'), ActIIB 
(Forward, 5' TTG GCT GCG TCT GGA AGG CT 3'; Reverse, 
5' TGC CAC GAC TGC TTG TCC TGA 3'), FLST288 
(Forward, 5' AGG GAA AGT GTA TCA AAG CAA AGT C 3'; 
Reverse, 5' AAC CTT GAA ATC CCA TAG GCA TT 3'); 
FLST315 (Forward, 5' TGC TCC TCC GGC GTA CTG 3'; 
Reverse, 5' CCG AGA TGG AGT TGC AAG ATC 3'); 
FLST-L3 (Forward, 5' CCA ACC CTG GCC AAG AAC T 3'; 
Reverse, 5' AAT GGA ACG GCC CAG AAA G 3'), Ubiquitin 
(Forward, 5' GAT CCA GGA CAA GGA GGG C 3'; 
Reverse, 5' CAT CTT CCA GCT GCT TGC CT3') and 
hydroxymethylbilane synthase (hmbs) (Forward, 5' TGC 
CAG AGA AAA GTG CCG TGG G 3'; Reverse, 5' TGC AGC 
TCA TCC AGC TTC CGT 3'), 18S (Forward, 5'-GCG AAT 
GGC TCA TTA AAT CAG TTA-3'; Reverse, 5'-TGG TTT 
TGA TCT GAT AAA TGC ACG-3'), p0 (Forward, 5' GAG 
GTC CTC CTT GGT GAA CA 3'; Reverse, 5' CCT CAT TGT 
GGG AGC AGA CA 3'). To avoid possible contamination 
by genomic DNA, primers were designed in different exons. 
The real-time PCR was performed using a commercial kit 
(LightCycler™ 480 SYBR-Green I Master, Roche, Barcelona, 
Spain). The relative amount of all mRNA was calculated using 
a comparative Ct method. The average value of 18S, hmbs and 
acidic ribosomal phosphoprotein p0 mRNA was used as the 
invariant control for all studies.
Western blotting. Gastrocnemius muscle was homogenised 
in 10 mmol/l HEPES (pH 7.5), 10 mmol/l MgCl2, 5 mmol/l 
KCl, 0.1 mmol/l EDTA, 0.1% Triton X-100, 1 mmol/l DTT, 
and 5 µl/ml of buffer of a protease inhibitor cocktail (Sigma, 
St. Louis, MO, USA). Tissue homogenates were then centri-
fuged at 7,000 rpm for 5 min at 4˚C, and the supernatants 
were collected. Protein concentrations were determined 
according to the method of bicinchoninic acid (Pierce 
Technology, Rockford, IL, USA). Equal amounts of protein 
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(50 or 100 µg) were heat-denatured in sample loading 
buffer [50 mmol/l Tris-HCl (pH 6.8), 100 mmol/l DTT, 2% 
SDS, 0.1% bromophenol blue, 10% glycerol], resolved by 
SDS-PAGE (10% polyacrylamide, 0.1% SDS), and trans-
ferred to Immobilon membranes (Immobilon polyvinylidene 
difluoride, Millipore, Billerica, MA, USA). The filters were 
blocked with 5% PBS non-fat dry milk and then incubated 
with polyclonal antibody anti-myostatin (Millipore). Mouse 
antibody anti-Na+, K+-ATPase α subunit (John Hopkins 
University, Baltimore, MD, USA) was used as the invariant 
control. Goat anti-rabbit horseradish peroxidase conjugate 
(BioRad, Hercules, CA, USA) and HRP-conjugated donkey 
anti-mouse immunoglobulin-specific monoclonal antibody 
(Jackson Immuno Research, West Grove, PA, USA) were 
used as secondary antibodies. The membrane-bound immune 
complexes were detected by an enhanced chemilumines-
cence system (EZ-ECL, Amersham Biosciences, Piscataway, 
NJ, USA).
Statistical analysis. Statistical analysis of the data was 
performed by means of the Student's t-test.
Results and Discussion
Fig. 1 shows the implantation of the Yoshida AH-130 ascites 
hepatoma caused significant decreases in the weight of the 
gastrocnemius (13%), EDL (18%) and tibialis (12%) muscles. 
Formoterol treatment significantly increased the weight of the 
above-mentioned muscles (Fig. 1). These data are in agree-
ment with previous results from our own laboratory (32).
Myostatin has been described as a negative regulator of 
muscle growth and its development, and is involved in several 
forms of muscle wasting, including the severe cachexia observed 
as a result of diseases such as AIDS and cancer (35,36). 
Table I. Effects of formoterol treatment on gastrocnemius muscle mRNA content of ubiquitin, myostatin, follistatin isoforms and 
ActIIB receptor and muscle protein content of myostatin in rats bearing the Yoshida AH-130 ascites hepatoma.
 C C + F  T T + F
Gastrocnemius muscle
  mRNA content
    Myostatin 100±21 140±19 102±23 160±60
    ActIIB 100±12 133±13 213±31b 106±27d
    FLSTL3 100±12   94±16 172±38 291±48b
    FLST315 100±21 108±28   42±14a 129±29d
    FLST288 100±13   55±10d   54±13a 105±10b,d
    Ubiquitin 100±36   90±16 439±83b 103±25e
Protein content
   Myostatin 40 kDa 100±19  115±14   98±14   53±12b,d
   Myostatin 26 kDa 100±16 108±13 106±10   72±7a,d
Heart
  mRNA content
    Myostatin 100±24   85±10   67±7   87±11
    ActIIB 100±15 125±13 126±17 140±23
    FLSTL3 100±12   83±13   82±8   94±13
    FLST315 100±7 118±21   98±15 116±31
    FLST288 100±33 111±21   74±13   94±15
    Ubiquitin 100±5   93±9 143±4c 119±9d
For more details see the Materials and methods section. Results are the mean ± SEM for 6 animals in each group. The results of gene and protein 
expression are expressed as a percentage of controls. C, control animals, T, tumour-bearing rats, F, formoterol-treated rats. Values that were found 
to be significantly different by the Student's t-test from the non-tumour-bearing animal groups are indicated by ap<0.05, bp<0.01 and cp<0.001. 
Values that were found to be significantly different by the Student's t-test from the non-treated animal groups are indicated by dp<0.05 and ep<0.01.
Figure 1. Muscle weights in rats bearing the Yoshida AH-130 ascites hepatoma 
treated with formoterol. Results are the mean ± SEM for 7 animals. Muscle 
weights are expressed as mg/100 g of initial body weight. GSN, gastroc- 
nemius; TIB, tibialis; EDL, extensor digitorum longus. C, control animals; T, 
tumour-bearing rats; F, formoterol-treated animals. Values that were found to 
be significantly different by the Student's t-test from the non-tumour-bearing 
animal groups are indicated by *p<0.05, **p<0.01 and ***p<0.001. Values that 
were found to be significantly different by the Student's t-test from the non-
treated animal groups are indicated by #p<0.05, ##p<0.01 and ###p<0.001.
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McFarlane et al have demonstrated that myostatin induces 
cachexia through a NF-κB-independent mechanism by antago-
nizing hypertrophy signaling through the regulation of the 
AKT-FOXO1 pathway (25). As with other TGF-β superfamily 
members, myostatin interacts with a serine/threonine trans-
membrane receptor known as activin IIB (ActIIB) (22,37,38). 
Binding of the ligand to ActRII leads to phosphorylation and 
activation of the activin type I receptor,  which in turn initiates 
intracellular signaling mediated by SMAD proteins (22,37,38). 
Although the levels of gene expression for myostatin were not 
affected by tumour burden (Table I), the cachectic animals 
presented a significant increase (113%) in the gastrocnemius 
muscle mRNA levels of the myostatin receptor (ActIIB). This 
increase indicates that muscle wasting in this experimental 
tumour model involved the myostatin system. Notably, the 
expression of the different isoforms of follistatin [FLST288 and 
FLST315 (39,40)], a protein with the opposite effects to those of 
myostatin, were significantly reduced as a result of the implan-
tation of the tumour (46 and 58% for FLST288 and FLST315, 
respectively, Table I). This observation further supports a role 
for the myostatin system in muscle wasting in the Yoshida 
AH-130 ascites hepatoma model.
Follistatin is a secreted protein capable of binding and 
neutralising the actions of any member of the TGF-β family 
of proteins such as myostatin. In addition to our finding 
that follistatin is decreased in tumour-bearing animals, 
two independent approaches provide clear evidence that 
downregulation of this gene contributes to the atrophic 
phenotype in cachectic muscles. One approach is based 
on the observation that follistatin is required to increase 
the muscle capillary density and improve endothelial cell 
function in ischemic mice and that its expression is associ-
ated with AKT1 signaling (41). This result indicates that 
follistatin downregulation in cachectic muscles leads to a 
decrease in AKT1 expression resulting in a decreased protein 
synthesis (41). The other approach, using transgenic mice 
and C2C12 cells overexpressing follistatin, demonstrated 
that follistatin over-expression in mouse skeletal muscle 
promotes hypertrophy and an oxidative fibre-type switch, 
leading to increased whole-body strength and fatigue resis-
tance; follistatin overexpression enhances myoblast fusion, 
resulting in hypertrophic myotubes in C2C12 cells, acting 
via regulation of the CnA-NFAT pathway (42). Our results 
are in agreement with those of Costelli et al who observed 
similar changes in both myostatin and follistatin mRNA levels 
in gastrocnemius muscles of tumour-bearing rats at day 4 
of tumour growth (36). However, at later stages of tumour 
growth (day 7, as used in the present study) the same authors 
observed increased myostatin and follistatin mRNA levels. 
The reasons for this discrepancy are not known.
No changes in myostatin, myostatin receptor or follistatin 
mRNA were observed in the heart of the tumour-bearing 
animals (Table I). This indicates that the myostatin system 
does not appear to be responsible for cardiac muscle wasting. 
Similar observations have been made in patients with chronic 
heart failure (43).
When the animals were treated with formoterol, a β-agonist 
with anti-cachectic potential (32), in addition to an anabolic 
action of skeletal muscle that was clearly reflected on increases 
in muscle weights [gastrocnemius (13%), tibialis (10%) and 
EDL (12%) (Fig. 1)], the β-agonist significantly decreased 
ubiquitin gene expression (Table I). This is a clear marker 
of protein degradation, a process that has extensively been 
described during muscle wasting (44-49). Formoterol treatment 
significantly increased the two follistatin isoforms (94% for 
FLST288 and 201% for FLST315) as well as the FLSTL3 
(69%), termed FLST-like 3. FLSTL3 is a protein that has 
recently been discovered to share significant structural and 
functional homology with follistatin (50). Moreover, treat-
ment significantly decreased the levels of expression of the 
myostatin receptor (50%) (Table I). In addition, formoterol 
treatment resulted in a significant decrease in the myostatin 
protein content [both active (32%) and inactive myostatin 
(46%)] of gastrocnemius muscle (Table I). It is clear that the 
antiwasting effects of formoterol involve the myostatin system. 
In conclusion, the results presented indicate that certain 
anabolic actions of formoterol on the skeletal muscle of 
cachectic animals may be mediated via the myostatin system. 
This treatment modality should therefore be regarded as a 
potential therapeutic target in cancer cachexia.
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